Lacosta, Ana-María
Pascual-Lucas, María
Pesini, Pedro
Casabona, Diego
Pérez-Grijalba, Virginia
Marcos-Campos, Iván
Sarasa, Leticia
Canudas, Jesus
Badi, Hassnae
Monleón, Inmaculada
San-José, Itziar
Munuera, Josep
Rodríguez-Gómez, Octavio
Abdelnour, Carla
Lafuente, Asunción
Buendía, Mar
Boada, Mercè
Tárraga, Lluis
Ruiz, Agustín
Sarasa, Manuel
Funding for this research was provided by:
Araclon Biotech
Article History
Received: 4 September 2017
Accepted: 11 January 2018
First Online: 29 January 2018
Ethics approval and consent to participate
: This study was approved by the independent ethics committee of the Barcelona Hospital Clinic and conducted in accordance with the ethical and scientific principles described in the Declaration of Helsinki and the International Conference on Harmonisation Guideline for Good Clinical Practice (CPMP/ICH/135/95), European guidelines for clinical trials (2001/20/CE), and Spanish legislation (Royal Decree 223/2004 of 6 February, which regulates clinical drug trials). All participants provided written informed consent before enrolment.
: Not applicable.
: AML, MPL, PP, DC, VPG, IMC, LS, JC, HB, IM, ISJ and MS are employees of Araclon Biotech Ltd. ISJ is a shareholder of Araclon Biotech Ltd. MS holds several patents related to Alzheimer’s disease diagnosis and treatment, and he is the founder, chief executive officer, chief scientific officer and one of the current shareholders of Araclon Biotech Ltd. AR reports receiving personal fees from Landsteiner Genmed, grants from the Innovative Medicines Initiative (IMI) ADAPTED project (European Commission), the IMI MOPEAD project (European Commission), Instituto de Salud Carlos III (ISCIII; Ministry of Health, Spain), Grifols and Fundación Bancaria “La Caixa” outside the submitted work. MBo reports receiving grants from the European Foundation for the Study of Diabetes/Lilly Mental Health and Diabetes Program 2014-2015, and IH2020-JTI-IMI2-2015-05 (European Commission) (Eli Lilly and AstraZeneca) MOPEAD project 2016-2018, as well as personal fees from Grifols, Janssen, Eli Lilly, MSD, Nutricia, Roche and Servier, outside the submitted work. JM, ORG, CA, AL, MBu and LT declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.